DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2016
INDEX
Cytochrome P450
CYP3A4, 897
CYP2C8, 897
CYP2C9, 897
drug metabolism and, 897
and H 1
receptor antagonists, 920
products of, 941
statins and, 897
Cytochrome P450, CYP26A1,
epidermal, 1805
Cytochrome P450s, 125, 125t
in metabolism, 127–130
Cytokines, 1745–1750
in central nervous system, 390
recombinant, 1022
Cytolytic reactions, 76
Cytophagic histiocytic panniculitis,
cyclophosphamide for, 1821
Cytosine arabinoside, 1698–1700
CYTOTEC (misoprostol), 952, 1837, 1849
Cytotoxic agents
in dermatology, 1820–1822
mechanism of action of, 1820t
CYTOVENE (ganciclovir), 1596t
D
DA. See Dopamine (DA)
Dabigatran etexilate, 865–866
DAB 389
–IL-2. See Denileukin diftitox
Dacarbazine, 1668t–1670t, 1686–1687
Dacryocystitis, 1781
bacterial, treatment of, 1781t
Dactinomycin, 1668t–1670t
for cancer, 1712–1713
Dale, Sir Henry, 189
Dalfopristin, 1535–1537
DAMGO, actions and selectivities of,
485t
Danazol, for endometriosis, 1840
DANOCRINE (danazol), 1840
Dantrolene, as antidote, 86t
Dapagliflozin, SLC transporters and,
102t
Dapsone, 1563–1564
adverse effects and side effects of,
1824
in dermatology, 1823–1824
dosage and administration of, 1824
mechanism of action of, 1820t, 1823
metabolism of, 128t
pharmacokinetics of, 1829t
polymorphisms and response to,
159t, 161t
side effects of, 138t
structure of, 1823
Dapsone hydroxylamine, 1824
Daptomycin, 1542–1543
pharmacokinetics of, 1830t
DARAMIDE (dichlorphenamide), 679t
Darbepoetin alfa, 1071–1073
Darier’s disease, retinoids for, 1811
Darifenacin, 231, 232, 232t
Darunavir, 1653–1654
pharmacokinetics of, 1830t
structure of, 1648f
Dasatinib
mechanism of action of, 1732
pharmacokinetics of, 1734
resistance, mechanisms of,
1732–1733, 1733f
structure of, 1732
therapeutic uses of, 1734
toxicity of, 1734
DAT. See Dopamine transporter (DAT)
Databases, genomic, 152, 153t
Date, of prescription, 1881–1882
Datura stramonium, 226
Daunorubicin, 1668t–1670t
DAWN. See Drug Abuse Warning
Network (DAWN)
DAYPRO (oxaprozin), 989
DβH. See Dopamine beta-hydroxylase
(DβH)
N-Dealkylation, 127, 128t
O-Dealkylation, 127, 128t
Deamination, 127, 128t
Deaths, top agents in drug-related, 80t
Debrisoquine, 156
polymorphisms and response to,
159t
DECADRON (dexamethasone), 1225t
Decamethonium
structure of, 259f
tubocurarine vs., 267–268
Declaration of Helsinki, 9
Decongestion, ocular, autonomic
agents for, 1786t
Decontamination
gastrointestinal, 83–84
of poisoned patient, 82–85
Decreased uptake, 91
DEET (N,N′-diethylmetatoluamide)
interactions with alitretinoin, 1811
interaction with bexarotene, 1811
Deferasirox, 1875–1876
Deferoxamine, 1875–1876
as antidote, 86t
DEFY (tobramycin sulfate), 1781t
Degarelix, structure of, 1764t
Dehalogenation, 127
Dehydroemetine, 1426
Dehydroepiandrosterone sulfate, 134
Delavirdine, 1626t, 1642–1643
Delayed afterdepolarization (DAD),
820, 822f, 825
Delayed hypersensitivity reactions, 76
Deletions, 147, 147f, 148
Delirium, 419–420
[D-Ala 2 ,Glu 4 ]deltorphin, actions and
selectivities of, 485t
DEMADEX (torsemide), 682–684, 683t,
790
Demeclocycline, and antidiuretic
response to vasopressin,
708
Dementia, 419–420
Demser, 783
DEMULEN 1/35 (ethinyl
estradiol/ethynodiol), 1835t
DEMULEN 1/50 (ethinyl
estradiol/ethynodiol), 1835t
DENAVIR (penciclovir), 1596t
DENDRID (idoxuridine), 1596t
Denileukin difitox, 1745
dosage and administration of, 1747t,
1750
pharmacokinetics of, 1750
therapeutic uses of, 1750
toxicity of, 1747t, 1750
Denileukin diftitox
adverse effects and side effects of,
1827
components, 1827
for cutaneous T-cell lymphoma,
1827
mechanism of action of, 1827
Denosumab, 1299
Dense-cored vesicles, 187
Dental caries, fluoride and, 1302
Dependence
on amphetamines, 299
ethanol, 640–641
Depolarization, cardiac cell, sodium
and calcium exchange in,
802f
DEPO-PROVERA (medroxyprogesterone),
1756, 1836
one-year failure rate, 1834t
Depression
angina pectoris with, recommended
treatment for, 769t
antidepressants for, 398–413
major, 421
serotonin and, 343
symptoms of, 397–398